Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238592 | 0.95 | LMNA (0.86) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL6393682 | 0.93 | LMNA (0.90) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL21056179 | 0.93 | LMNA (0.83) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL29163747 | 0.93 | KMT2A (0.79) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL11324430 | 0.90 | KMT2A (0.73) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL5085718 | 0.89 | KMT2A (0.92) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL27578 | 0.87 | LMNA (1.00) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL9537786 | 0.87 | KMT2A (0.81) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL18705328 | 0.86 | RAB9A (0.76) | LMNAKMT2ATDP1MEN1SLC6A2 | |
| SCHEMBL31354703 | 0.86 | RAB9A (0.76) | LMNAKMT2ATDP1MEN1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960681-B2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1449828-A2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | Nagase ChemteX Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-0989112-B1 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6284791-B1 | USEFUL AS AN ANTI-MICROBIAL AGAINST HELICOBACTER PYLORI | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0989112-A2 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | GCK, ADCY9, ADCY7 | LMNA 2895/4885KMT2A 2789/4885TDP1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.